Melanoma Misdiagnosis Claims in Ireland: How Staging Delays and Referral Failures Affect Your Claim

How does Breslow thickness affect a melanoma claim in Ireland?

Breslow thickness measures the depth of a melanoma from the skin surface to the deepest tumour cell, recorded in millimetres. Under the NCCP 2024 Clinical Guideline for Melanoma Staging and Surveillance [5], this single measurement drives AJCC staging, determines treatment, and forms the foundation of any negligence claim in Ireland. A tumour caught at 0.8 mm or less carries over 99% five-year survival and requires only a simple wide excision. The same tumour allowed to grow beyond 4.0 mm drops below 50% survival and typically demands sentinel lymph node biopsy, immunotherapy, and intensive surveillance imaging.

A detail that catches many claimants off guard: the legal question is not whether a GP missed the melanoma. The question is whether the delay allowed the Breslow depth to cross a staging threshold. The Breslow Threshold Test is the framework courts use to answer that question. Moving from T1 to T2 changes the treatment from a simple excision to excision plus sentinel lymph node biopsy (SLNB), with all the additional scarring, anxiety, and surveillance that brings.

Sources: AJCC 8th Edition staging. Irish cost data from PMC melanoma cost study (2023) [6]. Every case is different and outcomes vary.

Where does the Irish melanoma referral pathway break down?

Ireland operates a dedicated fast-track referral system for suspected melanoma. GPs use the NCCP National Pigmented Lesion GP Referral Form ³ to send patients electronically via Healthlink to a Pigmented Lesion Clinic (PLC). Patients flagged as urgent should be seen within two weeks. PLCs operate at the Mater, Beaumont, St Vincent's, South Infirmary Victoria (Cork), University Hospital Kerry, Naas, and Our Lady of Lourdes Drogheda, among other centres.

A peer-reviewed study published in the Irish Medical Journal [7] found that 65.3% of melanomas diagnosed through the Cork PLC were at an early stage, compared with 56.7% across County Cork generally. That 8.6 percentage-point improvement translates directly to thinner Breslow measurements and better survival outcomes. The PLC pathway exists because it works. When GPs bypass it, patients pay the price.

Common failure points in the referral chain

GP fails to recognise warning signs. The ABCDE criteria (asymmetry, border irregularity, colour variation, diameter over 6 mm, evolving) are widely known, but nodular melanomas can appear symmetrical and uniform. The "Ugly Duckling" sign, where one mole looks different from all of a patient's other moles, is an equally important clinical marker that many GPs overlook. The National Melanoma GP Referral Guidelines [8] specifically list the Ugly Duckling sign alongside ABCDE.

GP sends a routine referral instead of the NCCP electronic form. Placing a suspected melanoma on a general dermatology waiting list means the patient joins a queue of over 48,000 people, with 32% waiting more than 12 months according to the HSE Dermatology Model of Care (2019) [9]. The PLC pathway exists to bypass this queue entirely. Failure to use it is not just an administrative oversight. It's potentially negligent routing.

Triage error at the PLC. A referral flagged as "routine" when clinical features warranted "urgent" adds weeks or months to assessment. During that window, a melanoma can grow measurably deeper.

What standard of care applies to melanoma diagnosis in Ireland?

Irish medical negligence claims are assessed against the Dunne principles established in Dunne v National Maternity Hospital [1989]. Unlike in England and Wales, where the Bolam/Bolitho test applies, Irish law asks whether the doctor's conduct fell below the standard of a reasonably competent practitioner in the same specialty. The NCCP 2024 Clinical Guideline on Melanoma Staging and Surveillance ⁵ now sets the measurable benchmark against which dermatology care in Ireland is judged.

Dermoscopy as the expected standard

Dermoscopy (also called dermatoscopy or surface microscopy) involves examining a skin lesion under magnification with polarised light. Research consistently shows it improves diagnostic accuracy for melanoma by 20 to 30% compared with naked-eye examination alone. Irish dermatologists and many GPs with extended dermatology roles already use dermoscopy routinely. A specialist who examines a suspicious pigmented lesion without dermoscopy, where it was available, may have fallen below the expected standard of care in Ireland.

The Guidelines state that dermoscopy is standard practice, but in Circuit Court and High Court cases, the practical question is often whether a GP (who may not own a dermatoscope) met their duty by promptly referring to someone who does. The GP's obligation is to recognise that a lesion requires specialist assessment and to use the correct referral pathway. That obligation doesn't require the GP to diagnose melanoma themselves.

NCCP 2024 surveillance protocols as legal benchmarks

The most significant recent clinical development for melanoma in Ireland is the publication of the NCCP 2024 Guideline on Radiological Staging and Surveillance of Melanoma [10]. Before 2024, surveillance regimes varied between hospitals. The new guideline prescribes specific imaging protocols for higher-risk patients, and these now function as the legal yardstick for post-diagnosis care in Ireland.

Source: NCCP 2024 Clinical Guideline (PDF) ¹⁰. Protocols may differ for individual patients based on clinical judgment.

One detail that surprises clients: surveillance negligence is a separate category from diagnostic delay. Even after a melanoma is correctly diagnosed and treated, a failure to follow the 2024 surveillance protocol can ground its own negligence claim if missed metastasis results.

Which melanoma types are most commonly missed in Ireland?

Not all melanomas look like the dark, irregular mole that appears on awareness posters. Three types are missed disproportionately because they don't match the textbook image, and these account for a significant share of melanoma negligence claims.

Amelanotic and acral melanoma

Amelanotic melanoma accounts for 2 to 8% of all melanomas and appears pink, red, or skin-coloured. It lacks the dark pigment most people associate with melanoma. GPs frequently dismiss these lesions as eczema, psoriasis, dermatitis, pyogenic granuloma, or fungal infection. From handling melanoma negligence cases in Irish courts, we've found amelanotic lesions represent a disproportionate share of missed-diagnosis claims precisely because they don't trigger the expected "dark mole" pattern. The negligence lies in the failure to consider melanoma in the differential diagnosis for any persistent, non-healing, or changing skin lesion, regardless of colour.

Acral lentiginous melanoma develops on the palms, soles, or under fingernails and toenails. These areas receive minimal sun exposure, which leads both patients and doctors to discount skin cancer. The CUBED acronym (Coloured, Uncertain diagnosis, Bleeding, Enlargement, Delay in healing) is the appropriate clinical framework for assessing foot and hand lesions. For subungual (under-nail) melanoma specifically, Hutchinson's sign is the key clinical marker: pigment extending from beneath the nail plate into the surrounding nail fold or cuticle. When present, Hutchinson's sign is considered almost pathognomonic for melanoma and demands urgent biopsy. GPs who dismiss a longitudinal dark stripe under the nail as a fungal infection or subungual haematoma without checking for periungual pigmentation are falling below the standard of care. One detail that surprises clients: even a single brown or black line running the length of a nail warrants specialist referral in Ireland under current NCCP guidance.

Nodular melanoma and the Ugly Duckling sign

Nodular melanoma makes up 10 to 15% of cases and is the most lethal subtype because it grows vertically (deeper) rather than spreading outward across the skin surface. Nodular melanomas can appear symmetrical, uniformly coloured, and well-bordered, meaning they pass the traditional ABCDE screening test entirely. The ABCDE rule was designed for superficial spreading melanoma, not nodular types. Two alternative clinical tools catch what ABCDE misses. The "Elevated, Firm, and Growing" (EFG) criteria target the physical characteristics of nodular lesions. The Ugly Duckling sign takes a different approach: rather than evaluating a single mole in isolation, it compares the lesion to the patient's other moles. A mole that looks different from all the patient's other moles (the "ugly duckling") warrants referral even if it satisfies every ABCDE criterion individually. A GP who dismisses a firm, dome-shaped, rapidly growing lesion because "it's round and one colour" has relied on the wrong diagnostic framework. In Irish courts, expert dermatology evidence would likely characterise that decision as a failure to apply the appropriate standard of care for the lesion type presented.

How do you prove a delayed melanoma diagnosis caused harm?

Proving causation in melanoma negligence claims in Ireland requires linking the diagnostic delay to measurable stage progression. The legal test is not simply "did the doctor make a mistake?" It's "but for the negligence, would the patient's outcome have been materially better?"

Retrospective staging and tumour doubling times

A medico-legal expert can estimate the tumour's likely Breslow thickness at the time of the missed opportunity by applying known growth rates (called tumour doubling times). This is known as the Breslow Threshold Test. The test follows three steps: (1) estimate the tumour's likely Breslow depth at the date of the missed diagnosis, using doubling-time calculations, (2) compare that estimate to the Breslow depth recorded at eventual diagnosis, and (3) map both measurements to AJCC staging to determine whether the delay crossed a treatment threshold.

The doubling times matter because they differ substantially by subtype. Superficial spreading melanoma (the most common type) has a volume doubling time of roughly 50 to 155 days, meaning it grows relatively slowly and a six-month GP delay may still produce a measurable Breslow change. Nodular melanoma doubles far faster, approximately every 30 to 60 days, which means a three-month delay can be enough to push the tumour across a critical staging threshold. Lentigo maligna melanoma grows the slowest, with doubling times that can exceed 300 days. These rates are estimates derived from published growth-rate studies and vary between patients, but they give an expert pathologist the basis to calculate, with reasonable clinical confidence, what the melanoma's likely thickness was at the point the GP first saw it.

If the expert demonstrates the melanoma was likely T1a at the time the GP first saw it and T2 or T3 by the time it was finally biopsied, the delay demonstrably worsened the prognosis. The IRB statistics don't capture this kind of retrospective analysis, because medical negligence claims bypass the IRB entirely and go straight to court.

The "Loss of Chance" doctrine under Irish law

Irish law recognises the deprivation of a chance to obtain treatment as a compensable injury, established by the Supreme Court in Philp v Ryan [2004]. This doctrine is critical for melanoma claims. A six-month delay might shift a patient from 95% five-year survival to 75%. Even if the patient ultimately recovers, the stolen therapeutic window (when the tumour was thinner and treatment simpler) grounds a valid claim under Irish law.

The difference between assessment and acceptance often comes down to this: did the delay cross a staging threshold? If yes, the additional treatment, scarring, surveillance, and reduced survival probability are all compensable. The subsequent decision in Quinn v Mid-Western Health Board reaffirmed the balance of probabilities test in other medical negligence contexts, but Philp's "loss of chance" reasoning remains highly relevant to melanoma claims where statistical survival data can be mapped precisely to Breslow depth.

Compensation for melanoma negligence under Irish law

Compensation in melanoma misdiagnosis claims in Ireland is assessed under the Personal Injuries Guidelines (2021) ², formerly known as the Book of Quantum until 2021. Published by the Judicial Council, these guidelines set the framework for general damages (pain, suffering, and loss of amenity). Awards vary case-by-case based on injury severity, prognosis, age, and individual circumstances.

The Draft Second Edition (December 2024) proposes a 16.7% uplift based on HARMONISED Index of Consumer Prices inflation. It was submitted to the Minister for Justice in February 2025 but has NOT been approved by the Oireachtas as of February 2026. The 2021 figures remain current law. All awards depend on individual facts. Source: Judicial Council ².

Special damages: the cost of delayed treatment in Ireland

Beyond general damages for pain and suffering, special damages cover the actual financial losses caused by the negligence. An Irish-specific study published in Journal of Public Health (2023) found that managing Stage IV melanoma costs €122,985 per patient in Ireland, compared with €4,269 for Stage IA.

Lymphedema and ongoing care costs

One aspect the official guidance doesn't cover: lymphedema following completion lymph node dissection (CLND). When delayed diagnosis forces a full node clearance rather than a targeted sentinel node biopsy, the patient may develop permanent limb swelling requiring lifelong compression garments and physiotherapy. These ongoing costs are claimable as special damages and can extend over decades.

Psychiatric injury: fear of recurrence as a separate claim

The compensation dimension most melanoma patients don't know about: psychiatric injury is separately compensable on top of scarring and physical injury awards. The Personal Injuries Guidelines (2021) ² Chapter 4 sets the brackets: minor psychological damage €500 to €6,000, moderate €6,000 to €30,000, moderately severe €30,000 to €80,000, severe €80,000 to €150,000. For melanoma specifically, the fear-of-recurrence claim is particularly strong. Surveillance continues for 5 to 10 years with skin checks, ultrasound, and imaging scans. Every scan triggers anxiety about whether the cancer has returned. Clinical adjustment disorder, generalised anxiety, and PTSD from a delayed diagnosis are all recognised psychiatric injuries under Irish law when supported by a consultant psychiatrist's report. These awards stack on top of the scarring and physical injury compensation, they don't replace it.

What the Patient Safety Act 2023 means for melanoma claims in Ireland

The Patient Safety (Notifiable Incidents and Open Disclosure) Act 2023 [12] (Act 10 of 2023) came into effect on 26 September 2024. It requires health service providers to disclose specified serious incidents to patients and families, and to notify HIQA [13] within seven days.

A delayed melanoma diagnosis resulting in death or serious harm is a notifiable incident under the Act. The hospital must hold a formal open disclosure meeting with the patient or their family. An apology or information shared during open disclosure cannot be used as an admission of fault in civil proceedings (Section 10). Criminal penalties, including a Class A fine, apply to providers who fail to disclose without reasonable excuse.

The legal nuance that matters: Section 10 of the Act explicitly states that an open disclosure is NOT admissible as an admission of liability in court proceedings. However, the fact that you received an open disclosure letter is itself the strongest possible signal that the hospital's internal review identified a problem with your care. It tells your solicitor exactly where to look. If you've received an open disclosure meeting or letter about a delayed melanoma diagnosis, retain every document. The disclosure itself cannot be used as evidence of fault, but the underlying medical records, incident reports, and clinical audit findings that triggered the disclosure CAN be obtained through discovery in legal proceedings.

In practice, this means patients may discover diagnostic errors earlier than before. If you received an open disclosure meeting about a missed or delayed melanoma, that notification may start the clock on your "date of knowledge" for limitation purposes. Has the hospital been open with you? Under the Patient Safety Act 2023, you have a legal right to know if a diagnostic error contributed to your condition.

Time limits and date of knowledge for melanoma claims in Ireland

The limitation period for medical negligence claims in Ireland is two years from the "date of knowledge" under the Statute of Limitations (Amendment) Act 1991 ⁴. Unlike in England and Wales, where the limitation period is three years under the Limitation Act 1980, Ireland's two-year window is shorter and stricter.

For melanoma, the date of knowledge is not when the GP first dismissed the mole. It's the date when you knew or should have known both that you had melanoma AND that it resulted from negligent care. Skin cancer can remain asymptomatic for years, meaning a long gap between the breach and the discovery is common in melanoma claims.

Medical negligence claims are exempt from the Injuries Resolution Board (IRB), formerly known as the Personal Injuries Assessment Board (PIAB) until 2023. Claims go directly to court. The IRB route that applies to personal injury claims from road traffic accidents and workplace injuries does NOT apply to medical negligence. Waiting for an IRB that won't handle your claim wastes valuable time within the two-year limit.

How long does a melanoma negligence case take in Ireland?

Medical negligence cases in Ireland typically take 2 to 4 years from first solicitor instruction to resolution. Melanoma cases can resolve faster when liability is clear (the GP records show an obvious failure to use the NCCP referral pathway) or take longer when causation is disputed (expert disagreement over tumour doubling times and retrospective staging). Most cases resolve through negotiation or mediation without going to full trial.

The typical sequence runs: obtaining medical records (2 to 4 months), commissioning independent expert reports (4 to 8 months), issuing proceedings and exchanging pleadings (3 to 6 months), discovery and further expert evidence (6 to 12 months), and settlement negotiations or trial (6 to 18 months). The Courts Service annual reports show that medical negligence cases listed for High Court hearing have a median wait of approximately 18 to 24 months from setting down to trial date. Cases involving disputed causation, particularly where different experts disagree on tumour growth rates, tend to sit at the longer end of this range.

What evidence strengthens a melanoma negligence claim in Ireland?

Building a melanoma negligence case in Ireland requires clinical evidence connecting the diagnostic delay to stage progression. A quick settlement might be tempting, but leaving out future treatment costs or surveillance expenses would be a serious mistake.

Medical records and the blinded pathology review

GP records and clinical photographs. Request your full medical records under the Freedom of Information Act [15] or the Data Protection Acts. GP notes recording a patient's concern about a changing mole, combined with a failure to refer via the NCCP pathway, can be decisive. We frequently see cases where the GP photographed the lesion for a referral form but delayed sending it. The photograph proves the GP recognised something concerning, making the delay harder to defend.

Original biopsy slides. Obtaining the original histopathology slides for an independent "blinded review" by a separate consultant pathologist is one of the most important steps in building a melanoma negligence claim. "Blinded" means the reviewing pathologist reads the slides without seeing the original report, so their assessment is uninfluenced by the first pathologist's conclusion. Errors in Breslow thickness measurement, even by fractions of a millimetre, can change staging and treatment. The Royal College of Physicians of Ireland (RCPI) Faculty of Pathology sets the standards for melanoma reporting, including mandatory reporting of microsatellites, regression, and mitotic rate.

The timing matters more than most guides suggest: hospitals typically retain biopsy slides (paraffin blocks) for at least 10 years under HSE policy, but the sooner the independent review is commissioned, the better the tissue quality. Your solicitor can request the slides through a Section 8 notice or a direct medical records request. The independent pathologist's report then becomes the cornerstone of the causation argument. If the blinded review reveals the original slide was melanoma (not the benign diagnosis reported), or that Breslow depth was underestimated by the first pathologist, the claim gains a second negligence pathway: pathology error alongside any GP referral delay.

Expert reports and financial evidence

Independent expert oncology report. A consultant dermatologist or oncologist must provide a written report linking the delay to the worsened outcome. This report will typically include retrospective staging (estimating the tumour's thickness at the time of the missed diagnosis) and an assessment of how treatment and prognosis changed. The expert must practise in the relevant specialty. In Ireland, securing a suitable expert can take time, so starting early matters.

Financial evidence for special damages. Treatment receipts, travel costs for hospital visits, lost earnings, and evidence of ongoing care needs (surveillance scanning, compression garments for lymphedema, psychological support) all support the special damages component. This leads to the question of how much time you have to gather this evidence, which brings us to the limitation period.

What most guides miss about melanoma claims in Ireland

Immunotherapy access gap (2019 to 2021)

Between 2019 and May 2021, VHI-insured patients in Ireland could access adjuvant immunotherapy (pembrolizumab) for Stage III melanoma, while public patients on the HSE could not. The HSE approved nivolumab for adjuvant use in February 2021 and pembrolizumab in May 2021. Patients placed on "watch and wait" during this period whose melanoma recurred may have grounds relating to unequal access to treatment.

Surgical margin and pathology errors

Surgical margin negligence. Even after correct diagnosis, a surgeon who performs a narrow excision (insufficient safety margin) may leave residual tumour cells. The NCCP 2024 guidelines specify 1 cm margins for T1 melanomas and 2 cm margins for T2 and above. An excision with inadequate margins leading to local recurrence is a separate negligence pathway from delayed diagnosis.

Pathology errors are a distinct claim type. When a pathologist misreads a biopsy slide and reports melanoma as benign, proving the error requires a second pathologist to conduct a blinded review. Breslow measurement can vary slightly between pathologists. A reading of 0.9 mm versus 1.1 mm determines whether sentinel node biopsy was indicated, with all the consequences that follow.

Contributory negligence: does your own delay reduce the claim?

The question clients ask but rarely voice: "I noticed the mole changing months before I saw my GP. Does that destroy my claim?" Under the Civil Liability Act 1961 ¹¹, contributory negligence reduces damages proportionately but does NOT eliminate them. A patient is not expected to self-diagnose melanoma. The GP holds a higher duty of care than the patient, because the GP has the training, the dermoscope, and the NCCP referral pathway. In practice, a patient who delayed 4 to 8 months before presenting may see damages reduced by 10 to 25%, but the GP's failure to refer urgently once the patient DID present remains fully actionable. The critical question is what happened after you walked through the GP's door, not how long you waited to walk through it.

When a delay doesn't produce a viable claim

Not every delay produces a viable claim. If the melanoma was already Stage IIA when you first saw the GP, and the delay resulted only in progression to Stage IIB, the change in prognosis may be too small to prove significant harm. Irish courts require evidence of actionable injury caused by the negligence, not just evidence that a breach of duty occurred. In practice, many melanoma claims fail not because negligence didn't happen, but because the delay didn't cross a Breslow threshold. Applying the Breslow Threshold Test early saves clients from pursuing claims that cannot succeed on causation. Staging thresholds are what convert a breach into a compensable injury.

Five steps to take now if you suspect melanoma was missed in Ireland

1. Request your full GP and hospital records under the Data Protection Acts or Freedom of Information Act. Ask specifically for referral letters, clinical photographs, and any triage notes.
2. Obtain the original biopsy slides (paraffin blocks) and commission an independent blinded pathology review by a consultant histopathologist who has not seen the original report.
3. Construct your timeline from the date you first presented with a concern to the date of eventual diagnosis. Note every appointment, referral, and test. Identify the gap.
4. Check your limitation period. You have two years from your date of knowledge (when you knew or should have known the delay caused harm), not from the date of the original error.
5. Consult a solicitor experienced in medical negligence to assess whether the delay crossed a Breslow staging threshold that changed your treatment and prognosis. Medical negligence claims bypass the IRB and go directly to court.

References

1. National Cancer Registry Ireland, Cancer Trends No. 42: Skin Cancer (March 2025). NCRI cancer trends publication
2. Judicial Council, Personal Injuries Guidelines (2021). Judicial Council guidelines (PDF)
3. HSE/NCCP, GP Referral Forms and Guidelines for Cancer. HSE cancer referral forms
4. Statute of Limitations (Amendment) Act 1991. Irish Statute Book full text
5. HSE/NCCP, National Clinical Guideline: Radiological Staging and Surveillance of Patients with Cutaneous Melanoma (2024). HSE guideline announcement
6. O'Connor et al., “Melanoma-related costs by disease stage and phase of management in Ireland,” Journal of Public Health (2023). PubMed Central full text
7. Field S, Deady S, Fitzgibbon J, Murphy M, Comber H, “Improved malignant melanoma prognosis at a consultant-delivered multidisciplinary pigmented lesion clinic in Cork,” Irish Medical Journal 103(2):40–43 (2010). PubMed
8. St Vincent's University Hospital/NCCP, National Melanoma GP Referral Guidelines. NCCP referral guidelines (PDF)
9. HSE, Dermatology Model of Care (2019). HSE dermatology model of care (PDF)
10. HSE/NCCP, National Clinical Guideline: Radiological Staging and Surveillance of Patients with Cutaneous Melanoma (2024). NCCP guideline full text (PDF)
11. Civil Liability Act 1961. Irish Statute Book full text
12. Patient Safety (Notifiable Incidents and Open Disclosure) Act 2023. Irish Statute Book full text
13. Health Information and Quality Authority (HIQA). HIQA official site
14. Civil Liability and Courts Act 2004, Section 8. Irish Statute Book full text
15. Citizens Information, Freedom of Information. Citizens Information FOI guide
16. Medical Council of Ireland. Medical Council official site
17. HSE, Your Service, Your Say (Complaints). HSE complaints process